Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of June 2026. The report details the entry into a material definitive agreement on June 1, 2026, regarding a new equity financing arrangement.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sales agreement.
Material Changes and Agreements
- At-the-Market Offering: The Company entered into a Sales Agreement with Univest Securities, LLC to issue and sell up to $100,000,000 of Class A ordinary shares.
- Sales Method: Shares will be sold via an "at-the-market offering" on the Nasdaq Capital Market or other existing trading markets.
- Compensation: The Sales Agent is entitled to a commission of 3.00% of gross proceeds. Additionally, the Company will reimburse the agent $0.003 per share sold for trading and exchange fees.
- Registration: The offering is registered under the Company's shelf registration statement on Form F-3 (No. 333-291428).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk disclosed relates to the potential dilution of existing shareholders should the Company elect to sell shares under the agreement. The agreement includes customary representations, warranties, and indemnification provisions, and either party may terminate the agreement with written notice.
Investor Verification Checklist
- Verify the current market price of Class A ordinary shares to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific conditions precedent to sales.
- Check subsequent filings to determine if and when shares are actually sold under this agreement.
- Confirm the Company's current cash position to understand the necessity of this financing.